Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation

Radotinib (Supect™) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI). Other TKIs, including imatinib and nilotinib, were also developed for treatment of CML, and recent studies were increasing about the therapeutic effects of other TKIs on solid tum...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunol Res
Hlavní autoři: Kim, Kyung Eun, Park, Sunyoung, Cheon, Soyoung, Kim, Dong Yeon, Cho, Dae Jin, Park, Jeong Min, Hur, Dae Young, Park, Hyun Jeong, Cho, Daeho
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6330826/
https://ncbi.nlm.nih.gov/pubmed/30687767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/9580561
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky